ProQR Therapeutics

+$0.10 (+14.71%) As of 11:17 AM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PRQR and other ETFs, options, and stocks.

About PRQR

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.

CEO
Daniel Anton de Boer
Employees
181
Headquarters
Leiden, Zuid-Holland
Founded
2012

PRQR Key Statistics

Market cap
48.60M
Price-Earnings ratio
—
Dividend yield
—
Average volume
531.46K
High today
$0.845
Low today
$0.78
Open price
$0.8168
Volume
734.31K
52 Week high
$9.09
52 Week low
$0.53

PRQR Earnings

-$0.31
-$0.21
-$0.10
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure